EP1102993A1 - Procede pour deceler la presence de drogue, et solvant et solution de decomposition prevus a cet effet - Google Patents

Procede pour deceler la presence de drogue, et solvant et solution de decomposition prevus a cet effet

Info

Publication number
EP1102993A1
EP1102993A1 EP99938051A EP99938051A EP1102993A1 EP 1102993 A1 EP1102993 A1 EP 1102993A1 EP 99938051 A EP99938051 A EP 99938051A EP 99938051 A EP99938051 A EP 99938051A EP 1102993 A1 EP1102993 A1 EP 1102993A1
Authority
EP
European Patent Office
Prior art keywords
solvent
drugs
drug
solvent mixture
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99938051A
Other languages
German (de)
English (en)
Inventor
Josef Pucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dipro Diagnostics Handels GmbH
Original Assignee
Dipro Diagnostics Handels GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0034999U external-priority patent/AT3605U1/de
Application filed by Dipro Diagnostics Handels GmbH filed Critical Dipro Diagnostics Handels GmbH
Publication of EP1102993A1 publication Critical patent/EP1102993A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125—Digestion or removing interfering materials

Definitions

  • the present invention relates to a method for the rapid and immediate detection on site of drugs or drug substitutes present in solid form, to a solvent or solvent mixture and a digestion solution for use in such a method, and to an apparatus for carrying out the method.
  • the drug test strips which have been used up to now for the on-site detection of drugs in liquid form or of drugs in solution, therefore frequently indicate the presence or absence of drugs, without this corresponding to the actual circumstances, so that thus does not provide conclusive evidence of the actual presence of the drugs or drug substitutes, since a substance that interferes with the examination very often falsifies the drug test in the direction of a positive or negative result.
  • the invention therefore aims to satisfy the long-standing need for a safe and rapid test or detection method which can prove the presence or absence of drugs or drug substitutes in any substances, and above that In addition, such proof should be reliable and reproducible not only to provide an indication of the presence of drugs or drug substitutes, but also to enable a distinction to be made as to what type of drugs or drug substitutes the examiner is confronted with, a disorder or impairment caused by customary substances or masking substances added to the drugs should be avoided.
  • a method for the rapid and immediate detection on site of solid drugs or drug substitutes is made available, which is essentially characterized in that the drugs or drug substitutes without pretreatment, in particular without comminution, in one Digestion or reaction vessel are transferred, a solvent or a solvent mixture containing at least one organic solvent is added, and the suspension and / or solution containing the drugs or degenerative substitutes is subjected directly to a drug test method known per se, in particular with drug test strips .
  • a drug test method known per se, in particular with drug test strips .
  • the mixture of drugs or drug substitutes and the solvent or solvent mixture in the digestion or reaction vessel shaken, in particular shaken for at least 10 to 30 s. Shaking or moving the mixture in this way also ensures that a uniform suspension and / or solution can be obtained for a meaningful examination.
  • the method according to the invention is preferably further developed in such a way that, in the presence of resinous drugs or drug substitutes, the step of unlocking the solution step Drugs or drug substitutes are preceded at ambient temperature in a digestion solution, in particular containing a solubilizer, from a mixture of at least partially polar, organic solvents. If a substance to be investigated thus appears resinous or sticky, a further step of disintegrating the resinous substance at ambient temperature is carried out according to the invention before the dissolving step, the active constituents, namely, for example, morphine, codeine, only being added to the resinous substance.
  • Ethyl morphine, etc. is dissolved out of the resinous substance, in particular raw opium or hash resin, or the cells of the plant samples are broken open or destroyed, so that even as a layperson without chemical training, the substance of the actual drug consisting of the plant-like, resinous substances to dissolve out and subsequently convert them into a form by dilution with a solvent and / or a solvent mixture containing at least one organic solvent, in which a drug test can be carried out simply and directly, for example with the aid of known test strips.
  • extenders or substances which are known to adulterate drug tests in the laboratory to such an extent that the test appears negative and the sample is considered to be harmless are very often added to these substances.
  • extenders or masking substances are, for example, citric acid, which lowers the pH of the drug or the drug substitute in such a way that a commercially available drug test fails.
  • the method according to the invention is preferably further developed such that a solvent or solvent mixture buffered to pH 5.5 to 8.5 is used as the solvent or solvent mixture.
  • the method according to the invention is further developed such that an indicator or indicator mixture is added to the solvent or the solvent mixture.
  • an indicator or indicator mixture By adding an indicator or indicator mixture to the solvent or solvent mixture used in the method according to the invention, the indicator changes color outside the working area of the test strips, so that the indicator indicates that the drug test strips are functioning correctly.
  • a change in color from red to green is sought, the presence of the red indicator color indicating that the method for the rapid and immediate detection on site of solid drugs or drug substitutes may not work or be disturbed , and the presence of a green indicator color indicates the functioning of the method according to the invention.
  • the addition of an indicator or indicator mixture also makes it possible to clearly and unambiguously identify drugs which have been mixed with common additional substances or masking substances, such as citric acid, for example by the color change of the indicator when they are reacted with the solvent or solvent mixture.
  • Another object of the present invention is to provide a solvent or solvent mixture len, which can be used in a method mentioned above and which can safely and reliably dissolve all drugs or drug substitutes as they are usually traded or consumed and convert them into a solution suitable for the application of the detection method.
  • the solvent or solvent mixture according to the invention for use in a method for the rapid and immediate detection on site of drugs or drug substitutes present in solid form is essentially characterized in that the solvent or the solvent mixture containing at least one organic solvent from the Group consisting of monohydric alcohols with 1 to 5 carbon atoms, ketones with 3 to 8 carbon atoms, polyhydric alcohols and / or water is selected.
  • the solvent or the solvent mixture containing at least one organic solvent is selected from monohydric, lower alcohols, ketones with 3 to 8 carbon atoms, polyhydric alcohols and / or water
  • the solvent or solvent mixture is polar or weakly polar and can therefore dissolve almost all common drugs or drug substitutes, which are usually polar, organic macromolecules, with certainty to such an extent that the sensitive drug tests with drug test strips enable reliable detection of the dissolved sample.
  • a nonionic detergent in particular (octylphenoxyl) is preferred.
  • polyethoxyethanol, alkylphenol polyglycol ether and / or polyoxyethylene sorbitan monolaurate in an amount of 0.01 to 0.5 wt .-%, as a solubilizer is added.
  • Solubilizers are used in particular when molecules with a complicated structure or substances which are poorly or poorly soluble in common solvents quickly and without great effort from large amounts of solvents.
  • a nonionic detergent in low concentrations is chosen as the solubilizer in order to be able to dissolve even weakly polar to almost nonpolar drug or drug substitute molecules in a sufficient amount in the solvent or solvent mixture according to the invention.
  • the use of a non-ionic detergent also makes it possible to achieve a reduction in the surface tension, which facilitates or enables uniformly running tests and reproducible values.
  • a buffer is also preferably added to the solvent or solvent mixture according to the invention, which buffers the solvent or solvent mixture to a pH in which the subsequent functioning properly using the drug test strips.
  • the solvent or solvent mixture is particularly preferred by adding buffer solutions, in particular citrate buffer solution, acetate buffer solution, maleate buffer solution, phosphate buffer solution, triethanolamine-HCl-EDTA buffer solution, Tris buffer solution and glycine buffer solution, to pH 5.5 to 8.5, in particular 6.5 to 8.
  • the solvent or solvent mixture according to the invention is preferably further developed such that it additionally contains an indicator mixture consisting of at least two indicators selected from methyl red sodium salt, bromocresol green, phenolphthalein, 1- Contains naphthol benzene and methylene blue.
  • the solvent or solvent mixture additionally contains a preservative.
  • a solvent or solvent mixture that can be used for a particularly large number of drugs or drug substitutes that it is preferably from 2 to 20% by weight of ethanol, from 0.5 to 2% by weight of acetone, from 0.05 up to 0.2 mol / l phosphate buffer or tris (ydroxymethy1) aminomethane-HCl buffer solution, adjusted to about pH 7.0, about 0.1 to 0.4% by weight of polyoxyethylene sorbitan monolaurate and an indicator mixture, selected from Methyl red sodium salt, bromocresol green, phenolphthalein, 1-naphtholbenzene and methylene blue, 0.01 to 0.2% by weight of a preservative, in particular sodium azide, and the rest contains water.
  • Such a solvent or solvent mixture is characterized not only in that it can be used for almost all currently known drugs or drug substitutes, but also in that it is a solvent or solvent mixture acts that is stable over a long period of time, so that the trouble-free functioning of the solvent is ensured even after a long period of filling the same and the non-use of the solvent.
  • a protective protein in particular bovine serum albumin
  • bovine serum albumin makes it possible to improve the running properties when evaluating, for example, with a test strip known per se, in particular with essentially sharper limits and straight-line strips on such a test strip, so that reliable statements about the presence or absence of this - Can be taken from drugs or drug substitutes.
  • the addition or use of such a protective protein supports the likewise preferred use of detergents in the sense of improving or facilitating an evaluation.
  • a digestion solution according to the invention for use in a method according to the invention is essentially characterized in that the digestion solution consists of at least 80% by weight of polar, organic solvents, selected from ketones with 3 to 8 carbon atoms, monohydric alcohols with 1 to 5 carbon atoms, organic acetate, such as methyl, ethyl and propyl acetate, and a nonionic detergent, especially polyoxyethylene sorbitanone laurate.
  • Such a digestion solution can break down the resins and in particular break up the cells of the usually herbal drugs and release the active drug components, such as 11-nor- ⁇ ⁇ -THC or 11-nor- ⁇ ⁇ - THC, so that after further dilution with the invention Solvents or solvent can be directly mixed into the detection method for drugs or drug substitutes without the detection method being disturbed by the resins, which usually cannot be effectively dissolved.
  • such a digestion solution can be, for example, about 2 to 8% by weight of methyl ethyl ketone, 2 to 8% by weight of n-butanol, 2 to 8% by weight of ethyl acetate, 70 to 90% by weight of acetone and 0 0.1 to 0.5% by weight of nonionic detergent, as corresponds to a preferred embodiment of the invention.
  • a device according to the invention is in particular designed such that, in addition to commercially available drug test strips for detecting a wide variety of drugs or drug substitutes, it contains at least one container with the solvent or solvent mixture defined above and at least one container with the digestion solution described above.
  • the device according to the invention can contain further aids, such as spatulas, tweezers, special containers for dissolving the substances, a stopwatch, detection cards for drugs and the like.
  • aids such as spatulas, tweezers, special containers for dissolving the substances, a stopwatch, detection cards for drugs and the like.
  • a synthetic drug cocktail consisting of benzodiazepines, barbiturate and certain tricyclic antidepressants was mixed and one mixture additionally 100 wt .-% citric acid added as a masking substance.
  • the drug cocktail was in solid form, with benzodiazepine as well as the tricyclic antidepressants in tablet form and only the barbiturate in powder form was mixed into the drug cocktail.
  • a drug cocktail consisting of 1 tablet bezediaediazepine, 0.05 g barbiturate and 1 tablet of a tricyclic antidepressant, was mixed with 20 ml of an extraction solution consisting of a solvent mixture from a Tris buffer, Tris (hydroxymethy1) aminomethane-HCl , 2% by weight of ethanol, 0.2% by weight of polyoxyethylene sorbitan monolaurate, 0.05% by weight of sodium azide and the rest of water.
  • the solvent mixture contained a mixture of common indicators containing methyl red sodium salt, bromocresol green and phenolphthalein.
  • the solution had a pH of 7.40.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé pour déceler rapidement et directement, in situ, la présence de drogues ou de succédanés de drogues sous forme solide. Selon ce procédé, les drogues ou les succédanés de drogues sont transférés sans prétraitement, notamment sans broyage, dans un cuve de décomposition ou dans un réacteur, puis ils sont mélangés à un solvant ou à un mélange de solvants contenant au moins un solvant organique, et enfin la suspension et/ou la solution contenant les drogues ou les succédanés de drogues est soumise directement à un test de dépistage de drogues connu en soi, notamment au moyen d'une bandelette test. L'invention concerne en outre un solvant ou un mélange de solvants et une solution de décomposition correspondants, ainsi qu'un dispositif pour mettre en oeuvre ledit procédé.
EP99938051A 1998-08-04 1999-08-04 Procede pour deceler la presence de drogue, et solvant et solution de decomposition prevus a cet effet Withdrawn EP1102993A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AT134798 1998-08-04
AT134798 1998-08-04
AT34999 1999-05-19
AT0034999U AT3605U1 (de) 1999-05-19 1999-05-19 Verfahren zum nachweis von drogen sowie lösungsmittel und aufschlusslösung hiefür
PCT/AT1999/000195 WO2000008471A1 (fr) 1998-08-04 1999-08-04 Procede pour deceler la presence de drogue, et solvant et solution de decomposition prevus a cet effet

Publications (1)

Publication Number Publication Date
EP1102993A1 true EP1102993A1 (fr) 2001-05-30

Family

ID=25592419

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99938051A Withdrawn EP1102993A1 (fr) 1998-08-04 1999-08-04 Procede pour deceler la presence de drogue, et solvant et solution de decomposition prevus a cet effet

Country Status (7)

Country Link
US (1) US20010051379A1 (fr)
EP (1) EP1102993A1 (fr)
CA (1) CA2339224C (fr)
HU (1) HUP0105393A3 (fr)
SK (1) SK1572001A3 (fr)
WO (1) WO2000008471A1 (fr)
YU (1) YU7701A (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609749A2 (pt) * 2005-04-07 2011-10-18 Chata Biosystems sistema de acondicionamento de caminho de fluxo
US20080254550A1 (en) 2007-02-05 2008-10-16 Andrew Homer Nathaniel Drug detection kit and method
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
US20100249166A1 (en) 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
US8785712B2 (en) 2009-06-12 2014-07-22 Rx Disposal Solutions, Llc Pharmaceutical drug disposal kit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795221A (fr) * 1972-02-12 1973-08-09 Merck Patent Gmbh Procede et reactif rapide en vue de deceler des stupefiants
IL112152A (en) * 1994-12-26 2000-11-21 Identa Ltd Process and test kit for cocaine detection
DE19623356C2 (de) * 1996-06-12 1998-07-30 Tewe Elektronic Bernhard Wesse Verfahren zur Flüssigfütterung von Tieren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0008471A1 *

Also Published As

Publication number Publication date
US20010051379A1 (en) 2001-12-13
YU7701A (sh) 2003-01-31
HUP0105393A3 (en) 2003-08-28
CA2339224A1 (fr) 2000-02-17
HUP0105393A2 (hu) 2002-04-29
SK1572001A3 (en) 2001-09-11
WO2000008471A1 (fr) 2000-02-17
CA2339224C (fr) 2005-12-20

Similar Documents

Publication Publication Date Title
DE2208269C3 (de) Verfahren und Vorrichtung zum Schwangerschaftsnachweis
DE10112470A1 (de) Verfahren zur Proben-Identifizierung bei einem Säugetier sowie ein Kit zur Durchführung dieses Verfahrens
DE69114851T2 (de) Verfahren zur bestimmung indoler verbindungen, die in schweinefleisch geschlechtsgeruch hervorrufen, und für dieses verfahren zu benutzender probenbehälter.
DE69508795T2 (de) Verfahren und testzusammensetzung zum nachweis von kokain
EP1102993A1 (fr) Procede pour deceler la presence de drogue, et solvant et solution de decomposition prevus a cet effet
DE69731103T2 (de) Verfahren zur proteinextraktion
DE10026195A1 (de) Verfahren und Vorrichtung zum Identifizieren chemischer Substanzen
DD202762B5 (de) Verfahren zum Nachweis unangenehmen Geruches, wie etwa Ebergeruch
WO2003029813A2 (fr) Bande de test permettant de deceler des proteines prions
AT3605U1 (de) Verfahren zum nachweis von drogen sowie lösungsmittel und aufschlusslösung hiefür
EP1344058B1 (fr) Kit et procede de determination de l'etat redox dans l'urine
DE2029822A1 (de) Diagnostisches Produkt und Verfahren zum Nachweis der Nikotinsaureproduktion durch Mycobaktenen
DE2921023A1 (de) Zusammensetzung, testeinrichtung und verfahren zum bestimmen von urobilinogen in einer probe unter verwendung der zusammensetzung
DE102014012367B3 (de) Verfahren zum Bestimmen der Konzentration von Glucoraphanin und/oder von Sulforaphan in einer Pflanze
WO2009152543A1 (fr) Procédé d'immunochromatographie et système de test pour la détermination d'au moins un analyte dans une solution test à analyser
AT523658A1 (de) Analysevorrichtung zur Analyse einer vorzugsweise flüssigen Probe
DE2341061C3 (de) Verfahren zur laufenden Klassierung von krankheitsverdachtigen Zellproben für Diagnostikprüfungen
DE2206697C3 (de) Verfahren und Schnellreagenz zum Nachweis von Morphin und Morphinderivaten
DE102019122467B4 (de) Verfahren zur Durchführung von in vitro-Freisetzungsstudien
DE102005026133B4 (de) Verfahren zur Bestimmung der antioxidativen Aktivität von Stoffen und Stoffgemischen
AT507056B1 (de) Immunochromatographisches verfahren und testsystem zur bestimmung von wenigstens einem analyten in einer zu untersuchenden testlösung
DE2435759A1 (de) Verfahren und mittel zur bestimmung nichtionischer tenside
DE2206697B2 (de) Verfahren und schnellreagenz zum nachweis von morphin und morphinderivaten
WO2024052243A1 (fr) Marqueur de contrôle métabolisable pour le marquage endogène de l'urine
WO2000036423A1 (fr) Mise en evidence de la presence de composes methylenedioxy de la serie des amphetamines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT;LV

17Q First examination report despatched

Effective date: 20040423

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040904